Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Angiomax (bivalirudin) anticoagulant
Angiomax anticoagulant · 3 trials · 7 indications
: In-hospital acute procedural success, defined as the absence of death, Q wave myocardial infarction (MI), repeat coronary revascularization, and stroke (hemorrhagic or ischemic) at hospital discharge or Day 7 after surgery ('Day 7/discharge'), whichever occurs first.
| Name | Type | Description |
|---|---|---|
| Angiomax (bivalirudin) anticoagulant | DRUG | - |
Inclusion Criteria: 1. Patients \>18 years of age. 2. Symptoms of STEMI for at least 30 min within previous 12 hours AND * ST-segment elevation in at least 2 contiguous leads or new Left Branch Bundle Block (LBBB), OR existing LBBB with positive troponin * Residual high grade stenosis and as...
Angiomax (bivalirudin) is an anticoagulant studied in cardiovascular conditions including myocardial infarction, unstable angina, and thrombocytopenia. It has been evaluated in patients undergoing primary PCI for acute myocardial infarction, in acute coronary syndromes, and in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery bypass grafting.
Angiomax (bivalirudin) is developed by Novartis AG, which trades under the ticker NVS. Novartis is the company associated with the clinical development program for this anticoagulant across its studied cardiovascular indications.
Angiomax (bivalirudin) has been studied in Phase 3 clinical trials. The Phase 3 program includes completed studies in acute myocardial infarction, acute coronary syndromes, and thrombocytopenia, with no trials currently listed as active.
Angiomax (bivalirudin) has been evaluated in completed Phase 3 trials including NCT00093184 in acute myocardial infarction patients undergoing primary PCI, NCT00093158 comparing it with heparin in acute coronary syndromes, and NCT00073580 in patients with HIT/HITTS type II undergoing off-pump coronary artery bypass grafting.
Yes, Angiomax is the brand name for bivalirudin, so the two names refer to the same anticoagulant. Angiomax (bivalirudin) is a small molecule developed by Novartis AG for cardiovascular indications including myocardial infarction, unstable angina, and thrombocytopenia.
The Angiomax (bivalirudin) Phase 3 program enrolled approximately 13,800 patients in total across its completed studies. The largest trial, NCT00093158, compared Angiomax with heparin in acute coronary syndromes and enrolled 13,800 patients in the United States.